Publique en esta revista
Información de la revista
Vol. 2. Núm. 4.Julio - Agosto 2006
Páginas 161-220
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 2. Núm. 4.Julio - Agosto 2006
Páginas 161-220
Revisiones
DOI: 10.1016/S1699-258X(06)73045-5
Acceso a texto completo
Antipalúdicos: actualización de su uso en enfermedades reumáticas
Antimalarials: an update in rheumatic diseases
Visitas
22287
Mercedes Jiménez Palop??
Autor para correspondencia
mercedes@donpp.com

Correspondencia: Dra. M. Jiménez Palop. Servicio de Reumatología. Hospital Universitario Puerta de Hierro. San Martín de Porres, 4. 28035 Madrid. España.
Servicio de Reumatología. Hospital Universitario Puerta de Hierro. Madrid. España
Este artículo ha recibido
22287
Visitas
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Los antipalúdicos son antiguos fármacos utilizados desde el siglo XIX para el tratamiento de las manifestaciones cutáneas del lupus y de la artritis reumatoide. En las últimas décadas, estos fármacos han consolidado su uso en dichas enfermedades y han incorporado nuevos mecanismos de acción, ampliando sus perspectivas terapéuticas. Son el tratamiento de elección en las manifestaciones leves y moderadas del lupus eritematoso sistémico y se han asentado como terapia combinada en la artritis reumatoide. Han mostrado sus efectos beneficiosos sobre la aterosclerosis, así como un possible papel en el tratamiento precoz del síndrome antifosfolipídico. Finalmente, muestran una potencial utilidad en otras enfermedades reumáticas como el síndrome de Sjögren y el reumatismo palindrómico. Esta revisión trata de realizar una puesta al día del uso de estos fármacos en reumatología, así como del control de su toxicidad.

Palabras clave:
Antipalúdicos
Cloroquina
Hidroxicloroquina
Lupus eritematoso sistémico
Artritis reumatoide

Antimalarials are long-standing drugs that have been used since the nineteenth century for the treatment of skin rashes and lesions in lupus and rheumatoid arthritis. In recent decades, their use in these disorders has been consolidated, and new mechanisms of action have been incorporated, broadening the therapeutic perspectives of these drugs. Antimalarials are the treatment of choice in mild and moderate manifestations of systemic lupus erythematosus and are established as part of combined therapy in rheumatoid arthritis. They have been shown to have beneficial effects on atherosclerosis, as well as a possible role in the early treatment of antiphospholipid syndrome. Lastly, they have been shown to have a potential use in other rheumatic diseases such as Sjögren’s Syndrome and palindromic rheumatism. This review aims to provide an update on the use of these drugs in rheumatology and to discuss their toxicity profile.

Key words:
Antimalarials
Chloroquine
Hydroxychloroquine
Systemic lupus erythematosus
Rheumatoid arthritis
El Texto completo solo está disponible en PDF
Bibliografía
[1.]
F. Page
Treatment of lupus erythematosus with mepacrine
Lancet, 2 (1951), pp. 755-758
[2.]
D.J. Wallace
The History of antimalarial
Lupus, 5 (1996), pp. S2-S3
[3.]
D.J. Wallace
Is there a role for quinacrina (Atabrine) in the new millennium
Lupus, 9 (2000), pp. 81-82
[4.]
E. Toubi, I. Rosner, M. Rozenbaum, A. Kessel, T.D. Golan
The benefit ofcombining hydroxychloroquine with quinacrine in the treatment of SLE patients
Lupus, 9 (2000), pp. 92-95
[5.]
A.L. Scherbel, J.W. Harrison, M. Atdjan
Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis related diseases
Cleve Clin Q, 25 (1958), pp. 95
[6.]
D.E. Furst
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
Lupus, 5 (1996), pp. S11-S15
[7.]
T. Munster, J.P. Gibbs, D. Shen, B.A. Baethge, G.R. Botstein, J. Caldwell
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis
Arthritis Rheum, 46 (2002), pp. 1460-1469 http://dx.doi.org/10.1002/art.10307
[8.]
R.B. Landewe, M.S. Vergouwen, S.G. Goeei The, A.W. Van Rijthoven, F.C. Breedveld, B.A. Dijkmans
Antimalarial drug induced decrease in creatinine clearance
J Rheumatol, 22 (1995), pp. 34-37
[9.]
M. Rubin, H.N. Bernstein, N.J. Zvaifler
Studies on the pharmacology of chloroquine
Arch Ophthalmol, 70 (1962), pp. 474
[10.]
J. Aponte, M. Petrelli, N. Von Dawson
Liver enzyme levels in artritis patirnts treated with long-term bolus methotrexate
Arthritis Rheum, 35 (1992), pp. 126-128
[11.]
M.L. Jewell, D.P. McCauliffe
Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment
J Am Acad Dermatol, 42 (2000), pp. 983-987
[12.]
B. Pool, S. Ohkuma
Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages
J Cell Biol, 90 (1981), pp. 665-669
[13.]
R.I. Fox
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Sem Arthritis Rheum, 23 (1993), pp. 82-91
[14.]
R. Fox
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drugs development
Lupus, 5 (1996), pp. S4-S10
[15.]
R.I. Rynes
Antimalarial drugs in the treatment of rheumatological diseases
J Rheumatol, 36 (1997), pp. 799-805
[16.]
J. Bondeson, R. Sundler
Antimalarial drugs inhibit phospholipase A2 activation and induction of interleuk in 1β and tumor necrosis factor a inmacrophages: implications for their mode of action in rheumatoid arthritis
Gen Pharmac, 30 (1998), pp. 357-366
[17.]
G.M. Murphy, J.L.M. Hawk, I.A. Magnus
Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring
Brit J Dermatol, 116 (1987), pp. 379-386
[18.]
A. Wozniacka, A. Carter, D.P. McCauliffe
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Lupus, 11 (2000), pp. 71-81
[19.]
T.Q. Nguyen, J.D. Capra, R.D. Sontheimer
4-aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation
Lupus, 7 (1998), pp. 148-153
[20.]
H. Lafont, F. Chanussor, C. Dupuy, P. Lechene, D. Lairon, M. Charbonnier-Augeire
Influence of acute injection of chloroquine on the biliary secretion of lipids and lysosomal enzyme on rats
Lipids, 19 (1984), pp. 195-201
[21.]
J.L. Goldstein, G.Y. Brunschede, M.S. Brown
Inhibition of ptoteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A and Triton WR 1339
J Biol Chem, 250 (1975), pp. 7854-7862
[22.]
H.W. Chen, D.A. Leonard
Chloroquine inhibits cyclization of squaleneoxide to lanosterol in mammalians cells
J Biol Chem, 259 (1984), pp. 8156-8162
[23.]
A.C. Beynen, A.J. Van der Moolen, M.J.H. Geelen
Inhibition of hepaticcolesterol síntesis by chloroquine
Lipids, 16 (1981), pp. 472-474
[24.]
K.L.G. Svenson, H. Lithell, R. Hällgren, B. Vessby
Serum lipoprotein inactive rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment
Arch Intern Med, 147 (1987), pp. 1917-1920
[25.]
D.J. Wallace, A.L. Metzger, V.J. Stecher, B.A. Turnbull, P.A. Kern
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids
Am J Med, 89 (1990), pp. 322-326
[26.]
L.S. Tam, E.K. Li, C.W. Lam, B. Tomlinson
Hydroxychloroquine has nosignificant effect on lipids and apolipo proteins in Chinese systemic lupus erythematosus patients with mild or inactive disease
Lupus, 9 (2000), pp. 413-416
[27.]
H.N. Hodis, F.P. Quismorio, E. Wickham, D.H. Blankenhorn
The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus
J Rheumatol, 20 (1993), pp. 661-665
[28.]
M. Petri, C. Lakata, L. Magder, D. Goldman
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupuserythematosus: a longitudinal data análisis
Am J Med, 96 (1994), pp. 254-259
[29.]
A. Kavanaugh, B. Adams-Huet, R. Jain, M. Denke, J. McFarlin
Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus
J Clin Rheumatol, 3 (1997), pp. 3-8
[30.]
R. Munro, E. Morrison, A.G. McDonald, J.A. Hunter, R. Madhok, H.A. Capell
Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis
Ann Rheum Dis, 56 (1997), pp. 374-377
[31.]
P. Rahman, D.D. Gladman, M.B. Urowitz, K. Yuen, D. Hallett, I.N. Bruce
The cholesterol lowering effect of antimal arial drugs is enhanced in patients with lupus taking corticosteroid drugs
J Rheumatol, 26 (1999), pp. 325-330
[32.]
L.S. Tam, D.D. Gladman, D.C. Hallett, P. Rahman, M.B. Urowitz
Effect ofantimal arial agents on the fasting lipid profile in systemic lupus erythematosus
Rheumatol, 27 (2000), pp. 2142-2145
[33.]
E.F. Borba, E. Bonfá
Longterm beneficial effect of choloroquine diphosphateon lipoprotein profile in lupus patients with and without steroidtherapy
J Rheumatol, 28 (2001), pp. 780-785
[34.]
R.E. Phillips, S. Looareesuwan, N.J. White, P. Chanthavanich, J. Karbwang, W. Supanaranond
Hypoglycemia and antimal arial drugs: quinidine and release of insulin
BMJ, 292 (1986), pp. 1319-1321
[35.]
A. Quatraro, G. Consoli, M. Magno, F. Caretta, A. Nardozza, A. Ceriello
Hydroxychloroquine in decompensated treatment-refractory noninsulin- dependent diabetes mellitus. A new job for an old drug?
Ann Intern Med, 112 (1990), pp. 678-681
[36.]
M. Petri
Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis
Lupus, 5 (1996), pp. S16-S22
[37.]
K. Shojania, B.E. Koehler, T. Elliott
Hypoglycemia induced by hydroxychloroquinein a type II diabetic treated for polyarthritis
J Rheumatol, 26 (1999), pp. 195-196
[38.]
J.R. Loudon
Hydroxychloroquine and postoperative thromboembolism after total hip replacement
Am J Med, 85 (1988), pp. 57-61
[39.]
A.E. Carter, R. Eban, R.D. Perrett
Prevention of post-operative deep venous thrombosis and pulmonary embolism
BMJ, 1 (1971), pp. 312-314
[40.]
A.E. Carter, R. Eban
Prevention of postoperative deep venous trombosis in legs by orally administered hydroxychloroquine sulfate
BMJ, 3 (1974), pp. 94-95
[41.]
D.B. Pilcher
Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients
Am Surgeon, 41 (1975), pp. 761-766
[42.]
E.H. Hansen, P. Jessing, H. Lindewald, P. Ostergaard, T. Olesen, E.I. Malver
Hydroxychloroquine sulphate in prevention of deep venous thrombosis following of the hip, pelvis, or thoracolumbar spine
J Bone Joint Surg Am, 58 (1976), pp. 1089-1093
[43.]
D.O. Chrisman, G.A. Snook, T.C. Wilson, J.Y. Short
Prevention of venous thromboembolism by administration of hydroxychloroquine
J Bone Joint Surg Am, 58 (1976), pp. 918-920
[44.]
E.D. Cook, M.H. Dawson, R.M. Ibbotson, S.A. Bowcock, M.E. Ainsworth, M.F. Pilcher
Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations
J Bone Joint Surg Am, 59 (1977), pp. 496-500
[45.]
T.K. Wu, M.J. Tsapogas, F.R. Jordan
Prophylaxis of deep venous trombosis by hydroxychloroquine sulfate and heparin
Surg Gynecol Obstet, 145 (1977), pp. 714-718
[46.]
E. Johansson, K. Forsberg, H. Johnsson
Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement
Haemostasis, 10 (1981), pp. 89-96
[47.]
E. Bertrand, B. Cloitre, R. Ticolat, R.K. Bile, C. Gautier, G.O. Abiyou
Antiaggregation action of cholroquine
Med Trop, 50 (1990), pp. 143-146
[48.]
R. Nosal, V. Jancinova, M. Petrikova
Chloroquine inhibits atimulatedplatelets at the arachidonic acid pathway
[49.]
B.P. Madow
Use of antimalarial drugs as “desludging” agents in vascular disease processes
JAMA, 172 (1960), pp. 1630-1633
[50.]
M.H. Edwards, S. Pierangeli, X.W. Liu, J.H. Barker, G. Anderson, E.N. Harris
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice
Circulation, 96 (1997), pp. 4380-4384
[51.]
D.J. Wallace
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Arthritis Rheum, 30 (1987), pp. 1435-1436
[52.]
D.J. Wallace, M. Linker-Israeli, A.L. Metzger, V.J. Stecher
The relevance of antimalarial theraphy with regard to thrombosis, hypercholesterolemia and cytokines in SLE
Lupus, 2 (1993), pp. S13-S15
[53.]
M. Petri, Hochberg, D. Hellmann, D. Goldman
Incidence and predictorsof thrombotic events in SLE: protective role of hydroxychloroquine
Arthritis Rheum, 35 (1992), pp. S54
[54.]
G.A. McCarthy
Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years
Arthiritis Rheum, 43 (2000), pp. S1061
[55.]
Khamashta MA, Wallace DJ, editors. Antimalarial in rheumatology. Lupus. 1996;5 Suppl 1:S1-73.
[56.]
K.H. Yoon
Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in Antiphospholipid Antibody (Hughes’) Syndrome
J Rheumatol, 29 (2002), pp. 1574
[57.]
D.J. Wallace
Antimalarial agents and lupus
Rheum Dis Clin N Am, 20 (1994), pp. 243-263
[58.]
J.V. Christiansen, J.P. Nielsen
Treatment of lupus erytematosus with mepacrine: results and relapses during a long observation
Brit J Dermatol, 68 (1956), pp. 73-87
[59.]
M. Ziff, P. Esserman, C. McEwen
Observations on the course and treatment of systemic lupus erythematosus
Arthritis Rheum, 1 (1958), pp. 332-350
[60.]
E.L. Dubois, S. Martel
Discoid lupus erythematosus; an analysis of its systemic manifestations
Ann Intern Med, 44 (1956), pp. 482-496
[61.]
R.D. Rudnicki, G.E. Gresham, N.F. Rothfield
The efficacy of antimalarialsin systemic lupus erythematosus
J Rheumatol, 2 (1975), pp. 323-330
[62.]
The Canadian Hydroxychloroquine Study Group
A randomized studyof of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
New Engl J Med, 324 (1991), pp. 150-154 http://dx.doi.org/10.1056/NEJM199101173240303
[63.]
E. Tsakonas, L. Joseph, J.M. Esdaile, D. Choquette, J.L. Senecal, A. Cividino
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus
Lupus, 7 (1998), pp. 80-85
[64.]
H.J. Williams, M.J. Egger, J.Z. Singer, R.F. Willkens, K.C. Kalunian, D.O. Clegg
Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythrmatosus
J Rheumatol, 21 (1994), pp. 1457-1462
[65.]
I.M. Meinao, E.I. Sato, L.E. Andrade, M.B. Ferraz, E. Atra
Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
Lupus, 5 (1996), pp. 237-241
[66.]
E.F. Morand, P.I. McCloud, G.O. Littlejohn
Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis
Ann Rheum Dis, 51 (1992), pp. 1318-1321
[67.]
M. Petri
Hydroxychloroquine: past, present, future
Lupus, 7 (1998), pp. 65-67
[68.]
Y. Molad, A. Gorshtein, A.J. Wysenbeek, D. Guedj, R. Majadla, A. Weinberger
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of Israeli cohort
Lupus, 11 (2002), pp. 356-361
[69.]
B.J. Fessler, G.S. Alarcón, G. McGwin, J. Roseman, H.M. Bastian, A.W. Friedman
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual
Arthritis Rheum, 52 (2005), pp. 1473-1480 http://dx.doi.org/10.1002/art.21039
[70.]
S. Jessop, D. Whitelaw, F. Jordaan
Drugs for lupus erythematosus (Cochrane Review)
The Cochrane Library, Issue 2, John Wiley & Sons, Ltd., (2004)
[71.]
B.H. Hahn
Systemic lupus erythematosus and accelerated atherosclerosis
N Engl J Med, 349 (2003), pp. 2379-2380 http://dx.doi.org/10.1056/NEJMp038168
[72.]
M.J. Davis, A.D. Woolf
Role of antimalarial in rheumatoid arthritis –the Brithish experience
Lupus, 5 (1996), pp. S37-S40
[73.]
M.M. Khraishi, G. Singh
The role of anti-malarial in rheumatoid arthritis– the American experience
Lupus, 5 (1996), pp. S41-S44
[74.]
M.B. Suárez-Almanzor, E. Belseck, B. Shea, J. Holmik, G. Wells, P. Tugwell
Drogas antipalúdicas para la artritis reumatoidea
La CochraneLibrary plus en español, Update Software, (2000)
[75.]
W.D. Blackburn, H.M. Prupas, J.C. Silverfield, J.E. Poiley, J.R. Caldwell, R.L. Collins
Tenidap in rheumatoid arthritis. A 24-week double-bindcomparison with hydroxychloroquine-plus-piroxicam and piroxicam alone
Arthritis Rheum, 38 (1995), pp. 1447-1456
[76.]
P. Clark, E. Casas, P. Tugwell, C. Medina, C. Gheno, G. Tenorio
Hydroxy chloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial
Ann Intern Med, 119 (1993), pp. 1067-1071
[77.]
M.J. Davis, P.T. Dawes, P.D. Fowler, S. Clarke, J. Fisher, M.F. Shadforth
Should disease-modifying agents be used in mild rheumatoid arthritis
J Rheumatol, 30 (1991), pp. 451-454
[78.]
J.M. Esdaile, S. Suissa, J.B. Shiroky, D. Lamping, E. Tsakonas, D. Anderson
A randomized trial of hydroxychloroquine in early rheumatoidarthritis: the HERA study
Am J Med, 98 (1995), pp. 156-168
[79.]
D.T. Felson, J.J. Anderson, R.F. Meenan
Use of short-term efficacy/toxicitytradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinicals trials
Arthritis Rheum, 35 (1992), pp. 1117-1125
[80.]
M. Csuka, G.F. Carrera, D.J. McCarty
Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study
JAMA, 255 (1986), pp. 2315-2319
[81.]
N.A. Tialakos
Low-dose cytotoxic drug combianation therapy in intractablerheumatoid artritis: two years later
Arthritis Rheum, 29 (1986), pp. S79
[82.]
D.J. McCarty, J.G. Harman, J.L. Grassanovich, C. Oian, J.P. Klein
Combinationdrug therapy of seropositive rheumatoid arthritis
J Rheumatol, 22 (1995), pp. 1636-1645
[83.]
W.S. Wilke, J.D. Clough
Therapy for rheumatoid arthritis: combinationsof disease-modifying drugs and new paradigms of treatment
Semin Arthritis Rheum, 21 (1991), pp. 21-34
[84.]
P. Langevitz, N. Kaplinsky, M. Ehrenfeld, M. Pras, R.A Intractable
treatmentwith combined methotrexate, azathioprine and hydroxychloroquine
Br J Rheumatol, 28 (1989), pp. 271-272
[85.]
D.L. Scott, P.T. Dawes, E. Tunn, P.D. Fowler, M.F. Shandforth, J. Fisher
Combination therapy with gold and hydroxychloroquine in rheumatoidarthritis: a prospective, randomized, placebo-controlled study
Br J Rheumatol, 28 (1989), pp. 128-133
[86.]
D.R. Porter, H.A. Capell, J. Hunter
Combination therapy in rheumatoidarthritis–no benefit of addition of hydroxychloroquine to patients with asuboptimal response to intramuscular gold therapy
J Rheumatol, 20 (1993), pp. 645-649
[87.]
M. Martin
A combination of D-penicillamine and hydroxychloroquine for the treatment of rheumatoid arthritis
Ann Rheum Dis, 41 (1982), pp. 208
[88.]
T.W. Bunch, J.D. O’Duffy, R.B. Tompkin, W.M. O’Fallon
Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis
Arthritis Rheum, 27 (1984), pp. 267-276
[89.]
T. Gibson, P. Emery, R.D. Armstrong, A.J. Crisp, G.S. Panayi
Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis-a comparative study
Br J Rheumatol, 26 (1987), pp. 279-284
[90.]
K.L. Faarvang, C. Egsmose, P. Kryger, J. Podenphant, M. Ingeman-Nielsen, T.M. Hansen
Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial
Rheum Dis, 52 (1993), pp. 711-715
[91.]
J.F. Fries, G. Singh, L. Lenert, D.E. Furst
Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis
Arthritis Rheum, 33 (1990), pp. 1611-1619
[92.]
P. Seideman, F. Albertioni, O. Beck, S. Eksborg, C. Peterson
Chloroquinereduces the bioavailability of methotrexate in patients with rheumatoidarthritis. A possible mechanism of reduced hepatotoxicity
Arthritis Rheum, 37 (1994), pp. 830-833
[93.]
J.R. O’Dell, C.E. Haire, N. Erikson, W. Drymalski, W. Palmer, S. Eckiioff
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.?
Engl J Med, 334 (1996), pp. 1287-1291
[94.]
T. Mottonen, P. Hannonen, M. Leirisalo-Repo, M. Nissila, H. Kautiainen, M. Korpela
Comparison of combination therapy with single-drugtherapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group
Lancet, 353 (1999), pp. 1568-1573
[95.]
M. Calguneri, S. Pay, Z. Caliskaner, S. Apras, Kiraz, I. Ertenli
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis
Clin Exp Rheumatol, 17 (1999), pp. 699-704
[96.]
K. Puolakka, H. Kautiainen, T. Mottonen, P. Hannonen, M. Korpela, H. Julkunen
Impact of initial aggressive drug treatment with a combinationof disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial
Arthritis Rheum, 50 (2004), pp. 55-62 http://dx.doi.org/10.1002/art.11436
[97.]
D.J. Wallace
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review
Lupus, 5 (1996), pp. S59-S64
[98.]
R.I. Fox, E. Chan, L. Benton, M. Friedlaender, F.V. Howell
Treatment of primary Sjogren’s syndrome with hydroxychloroquine
Am J Med, 85 (1988), pp. 62-67
[99.]
R.I. Fox, R. Dixon, V. Guarrasi, S. Krubel
Treatment of primary Sjögren’ssyndrome with hydroxychloroquine: a retrospective, open-label study
Lupus, 5 (1996), pp. S31-S36
[100.]
A.A. Kruize, R.J. Hene, C.G. Kallenberg, O.P. Bijsterveld, A. Van der Heide, L. Kater
Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial
Ann Rheum Dis, 52 (1993), pp. 360-364
[101.]
L. González-López, J.I. Gámez-Nava, G. Jhangri, A.S. Russell, M.E. Suárez-Almazor
Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials
J Rheumatol, 27 (2000), pp. 41-46
[102.]
W. Youssef, A. Yan, A.S. Russell
Palindromic rheumatism: a response tochloroquine
J Rheumtol, 18 (1999), pp. 35-37
[103.]
D.D. Gladman, R. Blake, B. Brubacher, V.T. Farewell
Chloroquine therapy in psoriatic arthritis
J Rheumatol, 19 (1992), pp. 1724-1726
[104.]
B.H. Athreya, J.T. Cassidy
Current status of the medical treatment of children with juvenile rheumatoid arthritis
Rheum Dis Clin North Am, 17 (1991), pp. 871-889
[105.]
L.R. Bryant, K.F. Des Rosier, M.T. Carpenter
Hydroxychloroquine in the treatment of erosive osteoarthritis
J Rheumatol, 22 (1995), pp. 1527-1531
[106.]
B. Rothschild, L.E. Yakubov
Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD
Compr Ther, 23 (1997), pp. 327-331
[107.]
S. Ullberg, N.G. Lindquist, S.E. Sjostrand
Accumulation of chorio-retinotoxic drugs in the foetal eye
Nature, 227 (1970), pp. 1257-1258
[108.]
C.N. Hart, R.F. Naunton
The ototoxicity of chloroquine phosphate
Arch Otolaryngol Head Neck Surg, 80 (1964), pp. 407-412
[109.]
P.A. Phillips-Howard, D. Wood
The safety of antimalarial drugs in pregnancy
Safety, 14 (1996), pp. 131-145
[110.]
N.M. Buchanan, E. Toubi, M.A. Khamashta, F. Lima, S. Kerslake, G.R. Hughes
Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases
Ann Rheum Dis, 55 (1996), pp. 486-488
[111.]
A.L. Parke, B. West
Hydroxychloroquine in pregnant patients with SLE
Rheumatol, 23 (1996), pp. 1715-1718
[112.]
P. Goupille
Grossesse et polyarthrite rhumatoïde
Rev Rhum. (Suppl Pédagogique), 64 (1997), pp. 174SP-182SP
[113.]
G. Klinger, Y. Morad, C.A. Westall, C. Laskin, K.A. Spitzer, G., etal Koren
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases
[114.]
R.A. Levy, V.S. Vilela, M.J. Cataldo, R.C. Ramos, J.L. Duarte, B.R. Tura
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study
Lupus, 10 (2001), pp. 401-404
[115.]
N. Costedoat-Chalumeau, Z. Amoura, P. Duhaut, L.T. Huong Du, D. Sebbough, B. Wechsler
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group
Arthritis Rheum, 48 (2003), pp. 3207-3211 http://dx.doi.org/10.1002/art.11304
[116.]
M. Motta, A. Tincani, D. Faden, E. Zinzini, A. Lojacono, A. Marchesi
Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation
J Perinatol, 25 (2005), pp. 86-89 http://dx.doi.org/10.1038/sj.jp.7211208
[117.]
A. Al-Herz, M. Schulzer, J.M. Esdaile
Survey of antimalarial use in lupuspregnancy and lactation
J Rheumatol, 29 (2002), pp. 700-706
[118.]
H.N. Bernstein
Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy
Am J Med, 75 (1983), pp. 25-34
[119.]
M.F. Marmor, R.E. Carr, M. Easterbrook, A.A. Farjo, W.F. Mieler
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy
Ophthalmology, 109 (2002), pp. 1377-1382
[120.]
R. Araiza-Casillas, F. Cárdenas, Y. Morales, M.H. Cardiel
Factors associated with chloroquine-induced retinopathy in rheumatic diseases
Lupus, 13 (2004), pp. 119-124
[121.]
E.J. Nord, P.K. Shan, R.Z. Rinaldi, M.H. Wisman
Hydroxychloroquine cardiotoxicityin systemic lupus erythematosus: a report of 2 cases and review of the literature
Semin Arthritis Rheum, 33 (2004), pp. 336-351
[122.]
J.-P. Baguet, F. Tremel, M. Fabre
Chloroquine cardiomyopathy with conductiondisorders
Heart, 81 (1999), pp. 221-223
[123.]
A. Cervera, G. Espinosa, R. Cervera, J. Font, M. Ingelmo
Cardiac toxicitysecondary to long term treatment with chloroquine
Ann Rheum Dis, 60 (2001), pp. 301
[124.]
E. Casado, M. Larrosa, J. Gratacós, J.M. Martínez, I. Ojanguren, A. Sanjuán
Antimalarial myopathy: more frecuent than we though? A longitudinal study with 119 patients
Arthritis Rheum, 46 (2002), pp. S612
[125.]
J.A. Avina-Zubieta, E.S. Johnson, M.E. Suárez-Almanzor, A.S. Russell
Incidenceof myopathy in patients treated with antimalarials. Report of three cases and review of the literature
Br J Rheumatol, 34 (1995), pp. 166-170
[126.]
D.J. Wallace
Antimalarials-the “real” advance in lupus
Lupus, 10 (2001), pp. 385-387
Copyright © 2006. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica

Suscríbase al Newsletter

Opciones de artículo
Herramientas
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?